- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Marcel Devetten, MD | Authors
Refractory CML: Not All Forms of Resistance Are Equal
April 15, 2008
The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).